Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Consolidated Net Income (2019 - 2026)

Kymera Therapeutics has reported Consolidated Net Income over the past 8 years, most recently at -$84.2 million for Q1 2026.

  • Quarterly Consolidated Net Income fell 13.04% to -$84.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$359.5 million through Mar 2026, down 29.09% year-over-year, with the annual reading at -$349.8 million for FY2025, 33.56% down from the prior year.
  • Consolidated Net Income was -$84.2 million for Q1 2026 at Kymera Therapeutics, up from -$98.0 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at -$19.4 million in Q4 2023 and troughed at -$98.0 million in Q4 2025.
  • The 5-year median for Consolidated Net Income is -$57.6 million (2023), against an average of -$60.2 million.
  • Year-over-year, Consolidated Net Income surged 49.95% in 2023 and then plummeted 317.34% in 2024.
  • A 5-year view of Consolidated Net Income shows it stood at -$38.7 million in 2022, then skyrocketed by 49.95% to -$19.4 million in 2023, then plummeted by 317.34% to -$80.8 million in 2024, then decreased by 21.25% to -$98.0 million in 2025, then grew by 14.05% to -$84.2 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Consolidated Net Income are -$84.2 million (Q1 2026), -$98.0 million (Q4 2025), and -$92.6 million (Q3 2025).